Sharecast News
23 Mar, 2022 15:23 23 Mar, 2022 15:23

4basebio launches two new synthetic DNA products

dl 4basebio aim biotechnology pharmaceuticals research development logo
4basebioSharecast graphic / Josh White

Cell and gene therapy developer 4basebio announced the expansion of its synthetic DNA product offering on Wednesday.

The AIM-traded firm said, following its announcement last June on the development of its ‘hpDNA’ and ‘osDNA’ synthetic constructs, it had now added ‘opDNA’ and ‘oeDNA’ to its offering.

It said the launch reflected the “uniquely customisable characteristics” of its synthetic DNA technology.

The company described opDNA as a partially opened, linear, double-stranded DNA product, with each molecule featuring a hairpin on either the 3’ or 5’ end, with an opposite open end.

4basebio said the open end of the construct could include an overhang or blunt end, with the product “ideally suited” as a template for IVT production of mRNA.

oeDNA, meanwhile, was described as a linear open-ended, double-stranded DNA product where both 3’ and 5’ ends are open, adding that constructs could be generated with blunt ends, overhangs or any combination thereof.

The board said that like all of the firm’s DNA products, oeDNA was resistant to degradation by exonuclease, and thus suitable for in vivo applications.

It added that the format was ideal for genome editing by homology-directed repair (HDR).

“The development of our DNA product range over the past 12 months underscores the flexibility of our technology and our ability to customise DNA for particular uses,” said chief executive officer Dr Heikki Lanckriet.

“We are able to modify our DNA constructs for an individual customer’s specific application.

“Moreover, due to our synthetic process, we can move from receipt of a customer’s sequence to a first GMP-compliant multi-gram batch within three months, significantly quicker than plasmid alternatives.”

At 1400 GMT, shares in 4basebio were down 1.89% at 520p.


News Source: © 2022 Web Financial Group (UK) Limited. All rights reserved and terms of use apply.

Important Legal Notice about News Sources: Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news and we may not share the views of the author or publisher. We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.

The value of investments can fall and you may get back less than you invested.

 

Important Legal Notice about News Sources

Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news articles and we may not share the views of the author or publisher.

We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.

The value of investments can fall and you may get back less than you invested.